natgillin/translations-raw huggingface dataset:
The composition according to claim 28 for use in the prevention and/or treatment of neurodegenerative and/or autoimmune diseases and syndromes, especially of MS, and/or for use in spinal cord injury recovery; preferably for use in the prevention and/or treatment of MS. 
Pripravak u skladu sa zahtjevom 28 naznačen time da je naznačen time da je za upotrebu za prevenciju i/ili liječenje neurodegenerativnih i/ili autoimunih bolesti i sindroma, naročito MS, i/ili za upotrebu za oporavak ozljede leđne moždine; poželjno za upotrebu za prevenciju i/ili liječenje MS.
a polyclonal antibody prepared against a peptide corresponding to the C-terminal region of the AB42 peptide which binds specifically to AB42 without giving any substantial cross-reaction with AB40 
poliklonsko protutijelo dobiveno protiv peptida koji odgovara C-terminalnom području peptida AB42, koje se specifično veže na AB42, a ne pokazuje nikakvu značajnu ukriženu reakciju s AB40,
Advantageously, the pressure lowering agent selected from ARBs to be used in the composition of the present invention is selected from the group consisting of candesartan, irbesartan, losartan, and valsartan. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni ARB odabran 12 skupine koju čine kandesartan, irbesartan, losartan i valsartan.
Freeze-dried molded article that can be obtained in accordance with the method according to any of the embodiments 19 to 21. 
Liofilizirani oblikovani proizvod sukladno zahtjevu 1 do 6 ili koji se može dobiti sukladno postupku u zahtjevu 7, za uporabu kao farmaceutski agens.
The method according to any one of claims 1-6, where in choosing the internal reference bins IRB by a genetic algorithm the first candidate set is chosen from the candidate set on the basis of their FB values using Student range coefficient and at the same time on the basis of their CV values. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1-6, pri čemu pri odabiru internih referentnih skupina polja IRB putem genetičkog algoritma prvi komplet kandidata se odabire iz kompleta kandidata na osnovi njihove FB vrijednosti korištenjem studentskog koeficijenta opsega 1 u isto vrijeme na osnovi njihovih CV vrijednosti.
R18, R19, R21 and R22 each represents independently hydrogen or methyl; 
R'*,R', Ri RŽsvaki predstavlja neovisno vodik ili metil;
Said watering and/or tempering is carried out over a period of preferably several days, in particular over a period of more than two days, in particular over a period of two to three days. 
Poželjno je da se navedeno namakanje izvodi kroz razdoblje od nekoliko dana, naročito kroz razdoblje od više od dva dana, naročito kroz razdoblje od dva do tri dana.
A light source as claimed in claim 19, wherein the body and the plug are of vitreous material and the plug is sealed to the crucible by local melting of the material of the plug at the step and/or the counter-bore. 
Svjetlosni izvor u skladu s patentnim zahtjevom 16, naznačen time, da su retorta i čep izrađeni od staklenih materijala, a čep je hermetički spojen na retortu lokalnim topljenjem materijala od kojeg je izrađen čep na stepenici i/ili upustivom dijelu.
An anti-CD20 antibody formulation comprising a therapeutically effective amount of an anti-CD20 antibody, 10 to 100 mM sodium acetate, 25 to 100 mM sodium chloride, 0.5 to 5% arginine free base, 0.02 to 0.2 mM EDTA, 0.01 to 0.2 % polysorbate 80 and adjusted to pH 5.0 to 7.0, for use in the treatment of an immune disease and/or autoimmune disease. 
Formulacija protutijela anti-CD20, naznačena time, da obuhvaća od 20 do 300 mg/mL ofatumumaba, pri čemu formulacija nadalje obuhvaća od 10 do 100 mM natrijevog acetata, od 25 do 100 mM natrijevog klorida, od 0,5 do 5% slobodne baze arginina, od 0,02 do 0,2 mM EDTA, od 0,01 do 0,2% polisorbata 80, i podešava se na pH-vrijednost od 5,0 do 7,0. [image]
The composition according to claim 4, wherein the amount of neratinib maleate is about 41 weight percent; or wherein the amount of neratinib maleate is about 35 weight percent. 
Pripravak u skladu s patentnim zahtjevom 4, pri čemu je količina neratinib maleata oko 41 masenih postotaka; ili pri čemu je količina neratinib maleata oko 35 masenih postotaka.
step (b) comprises detecting a cell death-stable enzyme activity in the cells and conditioned medium of a portion of the cell culture medium containing cells of the tissue-engineered product; and 
(b) narušavanja integriteta membrane stanica u dijelu medija stanične kulture koji sadrži stanice produkta preinačenog-tkiva;
According to one embodiment, the VEGF antagonist or the alpha5beta1 antagonist is conjugated to a cytotoxic agent or a chemotherapeutic agent. According to another embodiment, the cytotoxic agent is a radioactive isotope or a toxin. 
Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5betal, za uporabu prema zahtjevu 10, naznačen/i time, da citotoksično sredstvo je radioaktivni izotop, kemoterapeutsko sredstvo ili toksin.
A process of manufacturing solid pharmaceutical composition containing cytisine as an active substance, characterized in that: 
Postupak proizvodnje čvrstog farmaceutskog sastava koji sadrži citizin kao aktivni sastojak prema zahtjevu 1, naznačen time da:
is hydrogen or C1-C4alkyl; and R4 are independently selected from the group consisting of hydrogen, —C(═O)R5, and —C(═O)CHR6—NH2; or 
R? i R* su neovisno odabrani iz skupine koja sadrži vodik, -C(=O)R", i -C(=O)CHR"-NH;; ili
from 15 to 60% by weight, preferably from 20 to 50% by weight, of at least one cement binder; 
(a) Portland vezivo cementa je od 20 do 50% po masi;
Acid addition salts may be produced from the free bases in known manner, and vice-versa. 
Kiselinske adicijske soli mogu se dobiti iz slobodnih baza na poznati način, i obrnuto.
The antibody or antigen-binding fragment or pharmaceutical composition for use according to any one of claims 4 to 7, wherein the use in medicine is the use in a method for the treatment of Crohn's disease or ulcerative colitis disease. 
Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 9, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja bolesti ulcerativnog kolitisa.
A method of culturing heterologous protein-secreting mammalian cells in a cell culture supernatant wherein the cell culture supernatant has a dissolved CO2 concentration of 1 to 10%, wherein the cell culture is a continuous culture maintained at a density of from 1.4x106 to 2.8x106 cells/ml. 
Postupak uzgoja sisavačkih stanica koje izlučuju heterologni protein u supernatantu kulture stanica, naznačen time što se supernatant kulture stanica održava na pH podešenom na X ± 0,05, gdje X ima vrijednost od 7,15 do 7,20, uz uvjet da je pH podešen na vrijednost veću od 7,10, gdje je kultura stanica kontinuirana kultura koju se održava uz gustoću od 1,4 × 106 do 2,8 × 106 stanica/ml.
X is selected from the group consisting of C, N, O, and S; 
X se bira iz skupine koja sadrži C, N, 0, i S; tje broj od 0, 1, 2, ili 3;
R8a is an optionally substituted C3-6 alkyl group, an optionally substituted C3-8 cycloalkyl group, an optionally substituted C3-8 cycloalkyl-C1-6 alkyl group, an optionally substituted aryl group, an optionally substituted ar-C1-6 alkyl group, an optionally substituted acyl group, an optionally substituted heterocyclic group or an optionally substituted heterocyclic C1-6 alkyl group; R9a is a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-8 cycloalkyl group or an optionally substituted aryl group; and R11, X2, X4a and X6a are as defined above)). 
a je po izboru supstituirana C3-6 alkilna skupina, po izboru supstituirana C3-8 cikloalkilna skupina, po izboru supstituirana C3-8 cikloalkil-C1-6 alkilna skupina, po izboru supstituirana arilna skupina, po izboru supstituirana ar-C1-6 alkilna skupina, po izboru supstituirana acilna skupina, po izboru supstituirana heterociklička skupina ili po izboru supstituirana heterociklička C1-6 alkilna skupina; a je atom vodika, atom halogena, po izboru supstituirana C1-6 alkilna skupina, po izboru supstituirana C3-8 cikloalkilna skupina ili po izboru supstituirana arilna skupina; i R11, X2, X4a i X6a su kako je gore definirano)), pri čemu su ar-C1-6 alkilna skupina i karboksilna zaštitna skupina kao što je gore definirano.
Or ConjE: where Ab is an antibody that binds to CD19, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1 or 2, optionally further comprising a VL domain having the sequence according to any one of SEQ ID NOs. 7, 8, 9, 10, 11 or 12; wherein the drug loading (p) of drugs (D) to antibody (Ab) is an integer from 1 to 8. 
ConjE pri čemu Ab je protutijelo koje se veže na CD19, gdje protutijelo obuhvaća VH-domenu koja ima sekvencu u skladu s bilo kojom od SEQ ID NO: 1 ili SEQ ID NO: 2, te opcionalno nadalje obuhvaća VL-domenu koja ima sekvencu u skladu s bilo kojom od SEQ ID NO: 7, 8, 9, 10, 11 ili 12; pri čemu opterećenost lijekom (p) od lijekova (D) prema protutijelu (Ab), iznosi cijeli broj od 1 do 8.
Consequently, the efficiency of the nano-fibrillar cellulose gel with respect to the total energy consumption in order to achieve a certain Brookfield viscosity is higher than the efficiency of a corresponding nano-fibrillar cellulose gel or suspension having been fibrillated in the absence of fillers and/or pigments or a corresponding gel or suspension not containing filler and/or pigment. 
Gel od nanofibrilarne celuloze u skladu s patentnim zahtjevom 15, HR P20171818 T1 naznačen time što viskoznost gela od nanofibrilarne celuloze prema Brookfieldu je manja od viskoznosti odgovarajuće suspenzije nanofibrilarne celuloze prema Brookfieldu jer je fibrilirana u odsutnosti punila i/ili pigmenata.
Use of an inhibitor of CXCR1 and CXCR2 for the preparation of an adjuvant medicament for the transplant of pancreatic islets in Type 1 diabetes patients. 
PATENTNI ZAHTJEVI 1. Inhibitor CXCRI i/ili CXCR2 za uporabu kao adjuvantni medikament za presađivanje otočića gušterače u pacijenata s dijabetesom tipa 1.
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-B-D-glucopyranoside or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to Claim 4, wherein said solid tumor is selected from the group consisting of: lung cancer, sarcoma, fibrosarcoma, pancreatic cancer, prostate cancer, and colon cancer. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 4, gdje je navedeni solidni tumor odabran iz grupe koja se sastoji od: raka pluća, sarkoma, fibrosarkoma, raka gušterače, raka prostate, i raka debelog crijeva.
Preferably, the suitable solvent used in the crystallization step is a mixture of ethyl acetate and i-propanol. 
Poželjno, prikladno otapalo koja se koristi u kristalizacijskom koraku je smjesa etil acetata 1 i-propanola.
LCDR3 is represented by SEQ ID NO: 19, and wherein the cytotoxic agent is a maytansinoid. 
-LCDR3S je predstavljena sa SEQ ID NO: 19, i pri čemu citotoksično sredstvo je majtanzinoid.
Furthermore, the third ring member preferably comprises one or more locating recesses disposed in an upper circumferential surface for engaging with correspondingly-shaped protrusions in a housing or container for preventing free rotation of the third ring member. 
Brojač prema bilo kojem zahtjevu od 1 do 13, naznačeno time da spomenuti treći prstenasti element (1502) sadrži jedan ili više udubljenja za pozicioniranje (1508a), (1508b), (1508c) koji se nalaze na gornjoj površini obujma za djelovanje sa odgovarajuće oblikovanim izbočenjima u kućištu kako bi se onemogućila slobodna rotacija spomenutog trećeg prstenastog elementa.
or a pharmaceutically acceptable salt or ester, thereof; 
Formula 11 ili njena farmaceutski prihvatljiva sol ili ester; pri čemu:
Fig. 6 schematically shows another perspective view of the beam-like block of wood being shown in Fig. 5; 
shematski prikazuje pogled na presjek bloka od drva koji ima oblik grade i koji je prikazan na slici 3;
each Yi is a beta-aggregating sequence independently selected from a stretch of 6 to 16 contiguous amino acids, at least 50% of which are hydrophobic amino acids, and in which at least one aliphatic residue or F is present, and if only one aliphatic residue or F is present, at least one, and preferably at least two, other residues are selected from Y, W, A, M and T; and in which no more than 1, and preferably none, P, R, K, D or E residue is present, and wherein at least one Yi is a stretch identical to or differing with no more than one amino acid substitution from a contiguous stretch of amino acids naturally occurring in a protein of a pathogenic organism; and each Zi is a linker and Zn is independently selected from a linker or nothing; 
svaki Yi je beta-agregacijska sekvencija nezavisno odabrana iz slijeda 6 do 16 susjednih aminokiselina od kojih je najmanje 50% hidrofobnih aminokiselina i u kojima je prisutan najmanje jedan alifatski ostatak ili F, i ako je prisutan najmanje jedan alifatski ostatak ili F je prisutan, najmanje jedan, a poželjno najmanje dva, ostali ostaci su odabrani od Y, W, A, M i T; i u kojem nije prisutan više od 1, a poželjno nijedan ostatak P, R, K, D ili E, i pri čemu barem jedan Yi je slijed identičan ili različit od ne više od jedne aminokiseline supstitucija iz susjednog proteina aminokiselina koje se prirodno pojavljuju u proteinu patogenog organizma; i svaki Zi je linker i Zn se neovisno bira između linkera ili ništa;
The method of claim 4, wherein R9 is selected from the group consisting of ethyl, isopropyl, and isobutyl. 
Spoj prema zahtjevu 6, naznačen time da R5 je odabran iz skupine koja sadrži -heterociklilR12, -arilR12, i -heteroarilR12.
Compounds of formulae (I) and (Ia) in optically pure form can be obtained from the corresponding racemates according to well-known procedures, e.g., HPLC with chiral matrix. 
Spojevi formula (1) i (Ia) u optički čistom obliku mogu se dobiti iz odgovarajućih racemata u skladu s dobro poznatim postupcima, npr. pomoću HPLC s kiralnom matricom.
In a further instance, the immunogenic composition comprises a Hib saccharide conjugate and at least two N. meningitidis saccharide conjugates wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of the at least two N. meningitidis saccharide conjugates. Alternatively, the Hib conjugate is present in a lower saccharide dose than the saccharide dose of each of the at least two N . meningitidis saccharide conjugates. 
Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 3-5, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije N. meningitidis seroskupina A (MenA). Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 3-6, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije N. meningitidis seroskupina W135 (MenW).
The reaction was quenched with 1N HCl (40 mL) and extracted with ethyl acetate (3×). 
Reakcija se prekine s IN HCI (40 mL) i ekstrahira etil acetatom (3x).
The organic layer is washed with brine then reduced in vacuo. 
Organski sloj se ispere sa zas. otopinom NacCI i zatim se ispari u vakuumu.
The additive according to the invention, in other words, the total of ternesite (clinker) and at least one source of rapidly available aluminum, is contained in the binder mixture in a proportion of 1 to 20% by weight, preferably 2 to 15% by weight and particularly preferred 5 to 10% by weight. 
Postupak sukladno barem jednom od zahtjeva 1 do 9, naznačen time što je ternesit klinker samljeven na finoću (prema Blaineu) veću od 10000 cm"/g, i 3 do 99%, i poželjno 5 do 50%, sadržaja faze klinker je prisutan kao X-zraka amorfne faze.
PM01183, or a pharmaceutically acceptable salt thereof, for use according to claim 8 wherein the cancer to be treated is selected from lung cancer, sarcoma, malignant melanoma, prostate cancer, pancreas carcinoma, gastric carcinoma, ovarian cancer, hepatoma, breast cancer, colorectal cancer, kidney cancer, brain cancer, leukemia and lymphoma. 
PM01183, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što se rak kojeg treba liječiti bira između raka pluća, sarkoma, raka prostate, karcinoma želuca, raka jajnika, hepatoma, raka dojke, kolorektalnog raka, raka bubrega, raka na mozgu.
Examples of disease states in which the compound of the invention may have utility include skin diseases such as eczema, psoriasis, allergic dermatitis neurodermatitis, pruritis and hypersensitivity reactions; inflammatory conditions of the nose, throat or lungs such as asthma (including allergen-induced asthmatic reactions), rhinitis (including hayfever), nasal polyps, chronic obstructive pulmonary disease, interstitial lung disease, and fibrosis; inflammatory bowel conditions such as ulcerative colitis and Crohn's disease; and auto-immune diseases such as rheumatoid arthritis. The compound of the invention may also have use in the treatment of conjunctiva and conjunctivitis. It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylaxis as well as the treatment of established conditions. 
Spoj formule (1), ili njegov fiziološki prihvatljiv solvat, namijenjen upotrebi u liječenju pacijenata u skladu s patentnim zahtjevom 4, naznačen time što upalno i/ili alergijsko stanje se bira između egzema, psorijaze, alergijskog dermatitisa, neurodermatitisa, svrbeža, reakcija preosjetljivosti, astme, rinitisa, nazalnih polipa, kronične opstruktivne plućne bolesti, intersticijske plućne bolesti, fibroze, ulceroznog kolitisa, Crohnove bolesti, reumatoidnog artritisa i konjujnktivitisa. Spoj formule (1), ili njegov fiziološki prihvatljiv solvat, namijenjen upotrebi u liječenju pacijenata u skladu s patentnim zahtjevom 5, naznačen time što upalno i/ili alergijsko stanje je alergijski dermatitis.
• optionally at least one additive selected from the group consisting of acids, inorganic wetting agents and acid phosphate adhesives; and 
opcionalno najmanje jedan aditiv izabran iz skupine koja se sastoji od kiselina, anorganskih ovlaživača i kiselih fosfatnih ljepila; i -
A cloning or expression vector comprising the nucleic acid according to claim 1 . 
Vektor kloniranja ili ekspresije, naznačen time, da obuhvaća jednu 1li više nukleinskih kiselina prema zahtjevu
The agonist for use according to claim 1, wherein the alpha adrenergic receptor agonist is selected from a selective alpha 1 adrenergic receptor agonist, a selective alpha 2 adrenergic receptor agonist, a non-selective alpha 1/alpha 2 adrenergic receptor agonist, an agent with alpha 2 adrenergic receptor agonist activity, and combinations thereof. 
Agonist za uporabu u skladu sa zahtjevom 1, naznačen time što je agonist alfa adrenergijskog receptora odabran od selektivnog agonista alfa 1 adrenergijskog receptora, selektivnog agonista alfa 2 adrenergijskog receptora, neselektivnog agonist alfa 1/alfa 2 adrenergijskog receptora, sredstva s aktivnošću agonista alfa 2 adrenergijskog receptora i njihovih kombinacija.
converting (S1701) a transport stream to a Physical Layer Pipe, PLP and generating a data slice including the PLP; 
pretvorbu (S1701) prijenosnog toka u PLP i dobivanje podatkovnog komada, uključujući PLP;
The isolated polynucleotide according to claim 14, encoding 
Izolirani polinukleotid prema patentnom zahtjevu 14, naznačen time, da on kodira:
each of the boosters is assignable to each of the computation nodes, and wherein said resource manager is arranged to perform the assignment by using the predetermined metric at a start of processing of said computation task and to update the assignment metric during said processing and thereby perform a dynamic assignment of boosters to computation nodes during run time by 
svaki pojačivač moguće je dodijeliti svakom od računalnih čvorova, i pri čemu je navedeni upravitelj resursa dizajniran da izvršava dodjelu koristeći unaprijed određenu metriku na početku obrade navedenog računskog zadatka i da ažurira metriku dodjele tijekom navedene obrade i tako izvršava dinamičko dodjeljivanje pojačivača računalnim čvorovima tijekom vremena izvođenja pomoću
A process for preparing Compound 2: wherein R5 and R6 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, alkylaryl, arylalkyl, heterocyclic and heteroaryl groups, or R5 and R6, together with the nitrogen to which they are attached, form a 3- to 6-membered heterocyclic compound containing 1-4 heteroatoms, said process comprising: converting (R)-butynol to Compound 3: 
O gdje svakog od Rs i Rs se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne, heterocikličke i heteroarilne skupine, ili Rs i R4, zajedno s dušikom na kojeg su HR P20100218 T1 vezani, tvore 3- do 6-eročlani heterociklički spoj s 1 -4 heteroatoma, naznačen time što navedeni postupak se sastoji u: (a) prevođenju (R)-butinola u Spoj 3:
The operating fork 23 can be moved up and down by means of the handle 25 that is connected to a cam 56. 
Radna vilica 23 se može pomicati gore i dolje pomoću ručke 25 koja je spojena na bregastu osovinu 56.
The method of claim 1 wherein the pharmaceutical composition is packaged together with instructions for using the composition to treat a cardiovascular disorder. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se pakira zajedno s uputama za upotrebi pripravak za liječenje kardiovaskularnog poremećaja.
Incubations are carried out for 2 hrs at room temperature. 
Inkubacije su provođene 2 sata na sobnoj temperaturi.
A compound according to claim 1, wherein R4 is hydrogen, methyl or ethyl. 
R* je vodik, metil, etil, vinil ili etilnil.
29.7 31.6 A method for treating materials containing a mixture of plastic and metal materials, said method comprising: 
Postupak za obradu materijala koji sadrže mješavinu plastičnih 1 metalnih materijala koji sadrže plemenite metale i aluminijum, naznačeno time, da je materijal elektronički otpad, navedeni postupak obuhvaća:
A vaccine composition comprising a compound in combination with an antigen or a recombinant expression vector encoding an antigen, wherein the compound has the following structure (IV): 
Pripravak cjepiva, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1-7, u kombinaciji s antigenom ili rekombinantnim ekspresijskim vektorom koji kodira antigen.
EP1284278 discloses, a conductive coating composition for textile materials comprising a PU polymer binder and 50-95 % wt. of a noble metal coated sphere with a diameter of 1-150 µm. 
EP1284278 opisuje smjesu vodljivog premaza za tekstilne materijale koji sadrži PU polimerno vezivno sredstvo i 50 95 % težinskog udjela kuglica presvučenih plemenitim metalom promjera od 1 - 150 um.
The pharmaceutical composition of claim 7, wherein the one or more heterologous domains enhance one or more of in vivo stability, in vivo half-life, uptake/administration, tissue localization or distribution, formation of protein complexes, and/or purification. 
Glikozilirani humani SAP polipeptid u skladu s patentnim zahtjevom 12, naznačen time, da jedna ili više heterolognih domena povećavaju jedno ili više od sljedećih svojstava: in vivo stabilnost, vrijeme in vivo polu-života, unos/primjenu, tkivnu lokalizaciju ili distribuciju, formiranje proteinskih kompleksa I / ili pročišćavanje.
screening the granules obtained in step (b) to remove particles, which are smaller than 150 µm. 
(c) prosijavanja granula dobivenih u koraku (b) kako bi se uklonile čestice manje od 150 um.
Further components, in particular used in the frame of serum-free cell culture media, are compounds such as glucose, glutamine, Na-pyruvate, insulin or ethanolamine (e.g. 
- - Ostale komponente, posebice korištene u okviru medija za kulturu stanica bez seruma, su spojevi poput glukoze, glutamina, Na-piruvata, inzulina ili etanolamina (pr.